Abcam, ab258501, Human LRRK1 knockout HeLa cell lysate

Size: 1Kit
LRRK1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon8 and 1 bp deletion in exon8 and 2 bp deletion in exon8.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon8 and 1 bp deletion in exon8 and 2 bp deletion in exon8.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LRRK1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LRRK1 also known as leucine-rich repeat kinase 1 is an important protein with a molecular mass of approximately 273 kDa. This protein belongs to the family of serine/threonine kinases and functions mechanically by phosphorylating other proteins a process critical for regulating various cellular processes. It is highly expressed in bone tissues with lower levels found in the liver and brain. LRRK1 also contains a GTPase domain which contributes to its kinase activity and is sometimes studied alongside its close relative LRRK2 due to structural similarities.
Biological function summary
LRRK1 plays a significant role in bone homeostasis and remodeling contributing to skeletal development and maintenance. LRRK1 does not form part of a larger complex but influences pathways involved in cytoskeletal dynamics and cellular motility. This protein is essential for osteoclast function where its kinase activity aids in the breakdown of bone matrix. Understanding its role in bone turnover helps researchers investigate potential therapeutic targets for bone-related conditions.
Pathways
LRRK1 is involved in signaling pathways related to bone resorption and remodeling. It participates in the RANK/RANKL/OPG pathway essential for osteoclast differentiation and activation. Additionally it interacts with proteins such as c-Src and Cbl which are critical in bone matrix dissolution and cellular adhesion processes. These interactions highlight LRRK1’s pivotal role in maintaining skeletal integrity through regulated bone degradation.
Research indicates that LRRK1 can impact conditions such as osteoporosis and Paget's disease of bone. Osteoporosis involves decreased bone mass and increased fracture risk which relates to dysregulated osteoclast activity in which LRRK1 may play a part. In Paget's disease abnormal bone remodeling processes occur possibly involving dysfunctions in LRRK1 signaling. The interaction of LRRK1 with LRRK2 is also relevant in this context as both enzymes share mechanistic features that might influence bone-related pathologies.